News: Overview

Keep up on the latest press releases and select stories about Graphite Bio below.


Press Release | May 4, 2021

Graphite Bio Appoints Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to Board of Directors

 

Press Release | April 27, 2021

Graphite Bio Appoints Jane Grogan, Ph.D., as Chief Scientific Officer

 

News Article | March 15, 2021

Stanford gene-editing startup raises $150M for sickle cell clinical trial, expansion into rare diseases

 

News Article | March 15, 2021

Next-gen gene editing upstart is grabbing the brass ring with a $150M crossover play to back its bid on a cure for sickle cell disease

 

Press Release | March 15, 2021

Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies

 

Press Release | February 24, 2021

Graphite Bio Expands Leadership Team with Appointment of Jerry Cacia as Chief Technical Officer

 

News Article | January 19, 2021

Clinical Trial Cleared for GPH101, First Potentially Curative SCD Therapy

 

Press Release | January 13, 2021

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID

 

Press Release | January 8, 2021

Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

 

Press Release | December 21, 2020

Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors

 

Press Release | December 14, 2020

Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease

 

Press Release | November 9, 2020

Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth

 

News Article | September 16, 2020

Endpoints: Versant Teams Up with Stanford Gene Editing Experts on a $45M Next-Gen Play — Marrying CRISPR and AAV to Fix Sickle Cell 

 

News Article | September 16, 2020

FierceBiotech: Graphite Bio debuts with $45M to cure sickle cell disease using gene edits  

 

Press Release | September 16, 2020

Graphite Bio Launches with $45 Million Series A Financing